JB
RCKT icon

Julian Baker’s Rocket Pharmaceuticals RCKT Stock Holding History

Julian Baker’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-552,079
Closed -$1.35M – 97
2025
Q2 		$1.35M Sell
552,079
-545,000
-50% -$2.76M 0.01% 80
2025
Q1 		$7.32M Buy
1,097,079
+1,000,000
+1,030% +$9.88M 0.08% 51
2024
Q4 		$1.22M Buy
+97,079
New +$1.46M 0.01% 88

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Julian Baker's RCKT Position: Q3 2025 in Review

Julian Baker sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 552,079 shares — an estimated $1.35M sold.

Julian Baker first reported a position in RCKT in Q4 2024 and held it in 3 quarters. The position peaked at $7.32M in Q1 2025. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

  • Julian Baker reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Julian Baker sold 552,079 Rocket Pharmaceuticals shares in Q3 2025, an estimated $1.35M.
  • Julian Baker first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Julian Baker's Rocket Pharmaceuticals position peaked at $7.32M in Q1 2025.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on Baker Bros. Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.